As Ewing sarcoma possesses one of the lowest mutation rates among all cancers (0.15 mutations per megabase)12,13, the nefarious activity of EWS/FLI has long been considered the ideal therapeutic target. This evidence concerns the gene FLII and Ewing sarcoma.